Affymetrix SNP array data for chronic lymphocytic leukemia samples
Ontology highlight
ABSTRACT: Although in 80% of CLL cases that require therapy is possible to achieve a complete remission using a combination of fludarabine, anti-CD20 in conjunction with cyclophosphamide and/or mitoxantrone, 20% of patients do not achieve disease control with this conventional approach. The main reason of complete remission failure is chemorefractoriness to fludarabine that occurs in up to 10% of patients requiring treatment. In order to identify new molecular predictors of refractoriness as well as druggable therapeutic targets, we combined next-generation sequencing and copy number analyses. Affymetrix SNP array analysis was performed according to the manufacturer's directions on DNA extracted from cryopreserved diagnostic samples.
ORGANISM(S): Homo sapiens
PROVIDER: GSE51711 | GEO | 2014/04/30
SECONDARY ACCESSION(S): PRJNA224700
REPOSITORIES: GEO
ACCESS DATA